A phase I/II trial to investigate the safety and efficacy of OPX-212 in neuromyelitis optica

Trial Profile

A phase I/II trial to investigate the safety and efficacy of OPX-212 in neuromyelitis optica

Planning
Phase of Trial: Phase I/II

Latest Information Update: 19 Sep 2017

At a glance

  • Drugs OPX 212 (Primary)
  • Indications Neuromyelitis optica
  • Focus Adverse reactions; Proof of concept; Therapeutic Use
  • Most Recent Events

    • 19 Sep 2017 According to a Acer Therapeutics media release, Acer Therapeutics merged with Opexa Therapeutics and the combined company has been named as Acer Therapeutics.
    • 10 Nov 2015 Planned initiation date changed from 1 Aug 2015 to 1 Jan 2016, according to a Opexa Therapeutics media release.
    • 10 Nov 2015 Opexa Therapeutics expects to submit the IND to the US FDA and start this study in the first half of 2016, according to the company media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top